We are a fast-growing European group dedicated to providing the pharma industry, healthcare professionals and their patients around the world with better access to medicines while also increasing the value of pharmaceutical products by extending and expanding their life cycle.
High-value market access and specialty distribution services through a unique infrastructure and geographical footprint. Our aim is to enable patients in key emerging markets to access specialty medicines through different approaches – named patient access and full-cycle commercialization.
We address the unmet needs of global patients by deploying our distribution infrastructure and navigating complex regulatory environments to supply unlicensed medicines via named patient programs
We represent specialty medicine biopharma companies in key emerging markets through licensing and partnership agreements
We cover such business components as regulatory approvals, pricing and reimbursement, medical affairs, and distribution and sales
Offices open by 2022 – Germany, Russia, Georgia, Slovakia
New offices to be opened in 2023 – Singapore, Turkey, Canada, Ukraine
Unique operational expertise in the emerging markets segment
(Russia + CIS, MENA and APAC)